The

SEP 0 9 2004 SS

9 2004 (25)							
Wholer the Par	perwork Reduction Act of 199	5, no person	s are required to respond to a collection	nt and Trade	mark Offic	e; U.S. D	PTO/SB/21 (02-04) ph 07/31/2006. OMB 0651-0031 EPARTMENT OF COMMERCE vs a valid OMB control number.
DEMARIE			Application Number	10/762,	,581		
Ti	RANSMITTAL		Filing Date	January	y 23, 20	04	
	FORM		First Named Inventor	Steven	N. Minl	(	
(to be used for	all correspondence after initia	l filing)	Art Unit	1646			
			Examiner Name	Unassi	gned		
Total Number of	Pages in This Submission	7+	Attorney Docket Number	BEP 30	)11		
		ENC	LOSURES (Check all tha	t apply)			
Amendme An Al  Extension  Express A  Information  Certified of Document  Response Incomplet	fter Final  ffidavits/declaration(s)  n of Time Request  Abandonment Request  on Disclosure Statement  Copy of Priority		Drawing(s)  Licensing-related Papers  Petition  Petition to Convert to a  Provisional Application  Power of Attorney, Revocation  Change of Correspondence Addr  Terminal Disclaimer  Request for Refund  CD, Number of CD(s)		Applof / App	rechnologies of the control of the c	osure(s) (please ow):
	SIGN	TURE C	OF APPLICANT, ATTORN	EY, OR	AGENT	÷	
Firm or	Arlir M. Amado, Re		,399				
Individual name	KRAMER & AMADO	D, P.C. <sub>e</sub>					
Signature	Soft	<b>∂-&gt;&gt;</b>					
Date	Sesten	The	9.2004				
		CERTIFIC	CATE OF TRANSMISSION	N/MAILIN	NG		
I hereby certify th sufficient postage the date shown b	at this correspondence is as first class mail in an e	being facsi	mile transmitted to the USPTO or dressed to: Commissioner for Pa	r deposited	d with the	United 8 0, Alexa	States Postal Service with ndria, VA 22313-1450 on
Typed or printed	name				····	*****	
Signature						Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: : Steven N. Mink, et al.

For: : METHODS OF TREATING

INFLAMMATION

Serial No. : 10/762,581

Filed : January 23, 2004

Art Unit : 1646

Examiner : Unassigned

Attorney Docket No. : BEP 3011

Confirmation No. : 3020

#### **INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

This Information Disclosure Statement is submitted:

under 3 / CFR 1.9 /(b), or
(Within three months of filing national application; or date of entry of international
application; or before mailing date of first office action on the merits; whichever
occurs last)

under 37 CFR 1.97(c) together with either a:

- \_\_ Certification under 37 CFR 1.97(e), or
- \_\_ a \$180.00 fee under 37 CFR 1.17(p), or
  - (After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)



Application No.: 10/762,581 Attorney Docket No.: BEP 3011

under 37 CFR 1.97(d) together with a:

- \_\_ Certification under 37 CFR 1.97(e), and
- \_\_ a petition under 37 CFR 1.97(d)(2)(ii), and
- a \$180.00 petition fee set forth in 37 CFR 1.17(i)(1).
- (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

X Applicants submit herewith Form PTO/SB/08A Information Disclosure Statement by Applicant together with copies, of patents, publications or other information of which applicants are aware, which applicants believe may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references is that this is the closest art of which Applicants are aware.

Applicants submit that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

In the event that the fees submitted prove to be insufficient in connection with the filing of this paper, please charge our deposit account number 50-0578 and please credit any excess fees to such Deposit Account.

Respectfully submitted, KRAMER & AMADO, P.C.

Date:

Arlir M. Amado

Reg. No. 51,399

KRAMER & AMADO, P.C.

Crystal Plaza One

2001 Jefferson Davis Highway

**Suite 1101** 

Arlington, Virginia 22202

Telephone No.: (703) 413-5000 Facsimile No: (703) 413-5048

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subtlibute for form 1449A/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

	Complete if Known	
Application Number	10/762,581	
Filing Date	January 23, 2004	
First Named Inventor	Steven N. Mink	
Art Unit	1646	
Examiner Name	N/A	
Attorney Docket Number	BEP 3011	

			U.S. PATENT	DOCUMENTS	
Examiner	Cita	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
Initials *	Cite No.1	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
		US-			
		US-			
		US-	•		
		US-			
	1	US-			
		US-			
		US-			
		US-			
	l	US-			
		US-			
	]	US-			
		US-		<u>                                     </u>	
		US-			
		US-			
		US-			

	FOREIGN PATENT DOCUMENTS							
Functions City	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant				
Examiner Initials*	Cite No. <sup>1</sup>	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T <sup>6</sup>		
				· · · · · · · · · · · · · · · · · · ·				
	<u> </u>							

Examiner Signature	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO Complete if Known Application Number 10/762,581 INFORMATION DISCLOSURE Filing Date January 23, 2004 STATEMENT BY APPLICANT First Named Inventor Steven N. Mink Art Unit 1646 (Use as many sheets as necessary) Examiner Name N/A of 4 BEP 3011 Sheet Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	,
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1	Parker JL et al., Am J Physiol., 1985, Jun;248(6 Pt 2):H818-26.	
	2	Parker MM et al., Annals of Internal Medicine, 1984, 100:483-490.	
	3	Lefer AM and Rovetto MJ, Proc Soc Exp Biol Med. 1970, May;134(1):269-73.	
	4	Lefer AM et al., Am J Physiol. 1967, Aug;213(2):492-8.	
	5	Parrillo JE et al., <i>J Clin Invest.</i> 1985, Oct;76(4):1539-53.	
	6	Gomez A et al., Anesthesiology, 1990, 73:671-685.	
	7	Jha P et al., Am J Physiol. 1993, May;264(5 Pt 2):H1402-10.	
	8	Eng JK et al., J Am Soc Mass Spectrom, 1994, 5:976-989.	
	9	Chittum HS et al., <i>Biochemistry</i> , 1998, 37:10866-10870.	
	10	http://www.nap.edu/readingroom/books/labrats/ Guide for the care and use of laboratory animals, © 1996, National Academy of Sciences.	
	11	Edman, P, Mol. Biol. Biochem. Biophysics, 1970, 8:211-255.	

Examiner		Date	
Signature	·	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

# Substitute for form 449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	3	of	4	

	Complete if Known	
Application Number	10/762,581	
Filing Date	January 23, 2004	
First Named Inventor	Steven N. Mink	
Art Unit	1646	
Examiner Name	N/A	
Attorney Docket Number	BEP 3011	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>		
	12	Rademacher TW et al., <i>Ann. Rev. Biochem.</i> 1988, 57:785-838.	<u> </u>		
	13	Boyum A, <i>Nature</i> , 1964, Nov;204(4096):793-794.			
	14	Grobler JA et al., Archives of Biochemistry and Biophysics, 1994, Sept;313(2):360-366.			
	15	Shugar D, Biochimica et Biophysica Acta, 1952, 8:302-309.			
	16	Chipman DM and Sharon N, <i>Science</i> , 1969, 165:454-465.			
	17	Rand-Meir T et al., <i>Biochemistry</i> , 1969, 8(10):4206-4214.			
	18	Li X et al., J Appl Physiol, 1998, 85(5):1693-1701.			
	19	Eichenholz PW et al., Am J Physiol. 1992, Sept;263(3 Pt 2):H668-75.			
	20	Finkel MS et al., <i>Science</i> , July 1992, 257:387-389.			
	21	Burgess P et al., Surgery, 1994, 115(1):16-21.			
	22	McDonald TE et al., Am J Physiol Heart Circ Physiol, 2000, 279:H2053-H2061.			
	23	Gu M et al., Can J Anaesth, 1998, 45(4):352-359.			
	24	Fleming, A., Proceedings of the Royal Society of London (Biology), 1922, 93:306-317.			
-	25	Briggs RS et al., The Journal of Histochemistry and Cytochemistry, 1966, 14(2):167-170.			
	26	Hansen NE and Andersen V, British Journal of Haematology, 1973, 24:613-622.			
	27	Hansen NE et al., The Journal of Clinical Investigation, 1972, 51:1146-1155.			
	28	Henning U et al., Molecular and Cellular Biochemistry, 1996, 160/161:41-46.			
	29	Ufret-Vincenty CA et al., Am J Physiol Cell Physiol, 2001, 281:C464-C474.			
·	30	Bennet ES, Biophysical Journal, 1999, 77:2999-3009.			

stitute for form 1449B/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	4	of	4

Complete if Known		
Application Number	10/762,581	
Filing Date	January 23, 2004	
First Named Inventor	Steven N. Mink	
Art Unit	1646	
Examiner Name	N/A	
Attorney Docket Number	BEP 3011	フ

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	31	Lollike K et al., <i>Leukemia</i> , 1995, 9:206-209.	
	32	Granton JT et al., Am J Respir Crit Care Med, 1997, 155:1977-1983.	
	33	Flecknell P, Laboratory Animal Anaesthesia: A practical introduction for research workers and technicians, 2 <sup>nd</sup> ed., London: Academic Press, 1996.	
	34	Crusch C et al., Am J Respir Crit Care Med, 2000, 161:517-526.	
	35 ·	Mink SN et al., Intensive Care Med, 1999, 25:733-743.	
	36	Maley F et al., Analytical Biochemistry, 1989, 180:195-204.	
	37	Nachbar MS et al., The Journal of Biological Chemistry, 1980, 255(5):2056-2061.	
	38	Crowley JF et al., Archives of Biochemistry and Biophysics, 1984, 231(2):524-533.	
	39	Nagata Y and Burger MM, The Journal of Biological Chemistry, 1974, 249(10):3116-3122.	
	40	Gilboa-Garber N and Mizrahi L, Can J Biochem, 1981, 59:315-320.	
	41	Hammarstrom S et al., Scand J Immunol, 1972, 1:295-309.	
	42	Varki A et al. Eds., Essentials of Glycobiology, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY: 1999.	